"10.1371_journal.pone.0002409","plos one","2008-06-18T00:00:00Z","Irene Kuhn; Paul Harden; Maxine Bauzon; Cecile Chartier; Julie Nye; Steve Thorne; Tony Reid; Shaoheng Ni; Andre Lieber; Kerry Fisher; Len Seymour; Gabor M Rubanyi; Richard N Harkins; Terry W Hermiston","Novel Technologies, Bayer Healthcare, Richmond, California, United States of America; Palo Alto Veterans Hospital and Stanford University, Palo Alto, California, United States of America; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, United States of America; Hybrid systems Ltd, Oxfordshire, United Kingdom","Conceived and designed the experiments: TH IK RH. Performed the experiments: ST LS IK PH MB CC JN SN AL KF. Analyzed the data: ST LS TH IK PH MB JN TR SN AL KF RH. Contributed reagents/materials/analysis tools: TR AL KF. Wrote the paper: LS TH IK PH MB GR RH. Other: Ran the explant studies used to define the tumor replication of the different viral agents, and the CD46 levels in the tumors: ST. Made the biodiverse viral pools: IK. Performed all the recombinatorial passaging and the initial selective passaging that generated ColoAd1: IK. Designed certain assays that were used in collecting and analyzing data provided in the paper: PH. Cloned coloAd1 as a plasmid: CC. Performed all in vivo studies with the liver metastasis model: SN AL. Discussed the design of the study and the interpretation of the results: GR.","The authors have declared that no competing interests exist.","2008","06","Irene Kuhn","IK",14,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA
